Valeant Pharmaceuticals International, Inc. (NYSE:VRX) recently announced that it has acquired a 19.9% stake in Brazilian biotech company, Pele Nova Biotecnologia S.A. 
Valeant paid less than $10 million for the deal. As per the terms of the deal, Valeant will have representation on Pele Nova’s Board of Directors, rights to future candidates in Brazil and first global product refusal rights. Additionally, Valeant will pay a reduced royalty percent on Regederm sales.
Regederm was included in … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards